VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection | Zendy

Teclegiorgis Gebremariam | Zendy; Nathan P. Wiederhold | Zendy; Annette W. Fothergill | Zendy; Edward P. Garvey | Zendy; William J. Hoekstra | Zendy; Robert J. Schotzinger | Zendy; Thomas F. Patterson | Zendy; Scott G. Filler | Zendy; Ashraf S. Ibrahim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection

Author(s) -

Teclegiorgis Gebremariam,

Nathan P. Wiederhold,

Annette W. Fothergill,

Edward P. Garvey,

William J. Hoekstra,

Robert J. Schotzinger,

Thomas F. Patterson,

Scott G. Filler,

Ashraf S. Ibrahim

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01437-15

Subject(s) - rhizopus arrhizus , mucormycosis , etest , amphotericin b , medicine , pharmacology , microbiology and biotechnology , biology , antibiotics , antifungal , biochemistry , pathology , lipase , enzyme

We studied the efficacy of the investigational drug VT-1161 against mucormycosis. VT-1161 had more potent in vitro activity against Rhizopus arrhizus var. arrhizus than against R. arrhizus var. delemar. VT-1161 treatment demonstrated dose-dependent plasma drug levels with prolonged survival time and lowered tissue fungal burden in immunosuppressed mice infected with R. arrhizus var. arrhizus and was as effective as high-dose liposomal amphotericin B treatment. These results support further development of VT-1161 against mucormycosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research